---
title: "Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296805475.md"
description: "H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Oculis Holding with an unchanged $26 price target, citing the advancement of privosegtor in optic neuritis and multiple sclerosis relapses. The FDA-supported PIONEER-1 study and Breakthrough Therapy designation support this view. Stifel Nicolaus also maintained a Buy rating with a $40 target."
datetime: "2026-08-24T14:55:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296805475.md)
  - [en](https://longbridge.com/en/news/296805475.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296805475.md)
generator: "portal-rs"
---

# Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Oculis Holding and keeping the price target at $26.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Yi Chen has given his Buy rating due to a combination of factors tied to Oculis’ advancing clinical and regulatory position for privosegtor. The company has initiated patient treatment in the pivotal PIONEER-1 optic neuritis study under an FDA Special Protocol Assessment, with Breakthrough Therapy and PRIME designations reinforcing the drug’s potential to become a first-in-class neuroprotective option.

In addition, Oculis is pursuing a capital-efficient expansion of privosegtor into acute multiple sclerosis relapses, leveraging existing optic neuritis data and an FDA-supported path that avoids new preclinical work. This dual-indication strategy, combined with the validated Phase 2 neuroprotective signal and streamlined development plan, underpins the unchanged $26 price target and supports maintaining a Buy recommendation.

In another report released on August 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating](https://longbridge.com/en/news/295013233.md)
- [Immunic posts investor overview presentation on multiple sclerosis strategy](https://longbridge.com/en/news/297956174.md)
- [Nkarta to present initial Phase 1/2 autoimmune data for CAR-NK therapy NKX019 at ACR Convergence 2026](https://longbridge.com/en/news/298306719.md)
- [Will FDA Fast Track for YUTREPIA in Raynaud’s Phenomenon Reshape Liquidia’s (LQDA) Narrative](https://longbridge.com/en/news/298038188.md)
- [Zenas Biopharma outlines obexelimab regulatory filings, pipeline milestones in corporate presentation](https://longbridge.com/en/news/298356646.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**